| 查看: 823 | 回复: 1 | |||
marineman至尊木虫 (知名作家)
爱八卦爱生活
|
[求助]
iPath2为何经常无法访问? 已有1人参与
|
|
http://pathways.embl.de 经常无法访问,可其他人都说可以。有时候上去了,输出结果图片也不成功。 Nucleic Acids Res. 2011 Jul;39(Web Server issue):W412-5. doi: 10.1093/nar/gkr313. Epub 2011 May 5. iPath2.0: interactive pathway explorer. Yamada T1, Letunic I, Okuda S, Kanehisa M, Bork P. Abstract iPath2.0 is a web-based tool (http://pathways.embl.de) for the visualization and analysis of cellular pathways. Its primary map summarizes the metabolism in biological systems as annotated to date. Nodes in the map correspond to various chemical compounds and edges represent series of enzymatic reactions. In two other maps, iPath2.0 provides an overview of secondary metabolite biosynthesis and a hand-picked selection of important regulatory pathways and other functional modules, allowing a more general overview of protein functions in a genome or metagenome. iPath2.0's main interface is an interactive Flash-based viewer, which allows users to easily navigate and explore the complex pathway maps. In addition to the default pre-computed overview maps, iPath offers several data mapping tools. Users can upload various types of data and completely customize all nodes and edges of iPath2.0's maps. These customized maps give users an intuitive overview of their own data, guiding the analysis of various genomics and metagenomics projects. |
» 猜你喜欢
含氟糖皮质激素的外用抗炎利器醋酸氟轻松
已经有0人回复
阿莫奈韦(Amenamevir):解旋酶-引物酶靶向分子的结构特征与合成路径全解析
已经有0人回复
化学工程及工业化学论文润色/翻译怎么收费?
已经有88人回复
利瑞鲁单抗:靶向KIR的NK细胞检查点工具抗体,结构基础与科研应用全解析
已经有0人回复
Wnt-C59:PORCN靶向化学探针,Wnt信号通路阻断机制与科研应用全解析
已经有0人回复
Fexaramine:肠道限制性FXR化学探针,结构特征与信号通路研究全解析
已经有0人回复
NVS-STG2:靶向STING跨膜域的分子胶类激动剂,结构特征与寡聚化机制研究全解析
已经有0人回复
DOTA-GPC3肽(CAS 3066439-94-6):双功能分子探针前体的结构特征与标记应用解析
已经有0人回复
科研用 TLR7/8 双激动剂怎么选?现货与质控要点
已经有0人回复
SEL120-34A HCl:CDK8/CDK19高选择性激酶抑制剂
已经有0人回复
晋鹏
版主 (知名作家)
- MolEPI: 6
- 应助: 626 (博士)
- 贵宾: 0.096
- 金币: 27592.6
- 散金: 1052
- 红花: 288
- 沙发: 2
- 帖子: 5663
- 在线: 726.4小时
- 虫号: 1183978
- 注册: 2011-01-05
- 性别: GG
- 专业: 生物信息学
- 管辖: 农林

2楼2017-10-07 20:42:16










回复此楼